



03rd November, 2017

✓ The Dy. General Manager (Listing Dept.)
BSE Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Press Release – Torrent Pharma acquires Branded Formulation Business of India and Nepal of Unichem Laboratories Limited

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015 and approval of the Board of Directors earlier today, we would like to inform that the Company has entered into a definitive binding agreement with Unichem Laboratories Limited to acquire its branded formulation business of India and Nepal as going concern on slump sale basis.

A Press release, containing the transaction details, which is being submitted to the media is enclosed herewith for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

A handwritten signature in black ink, appearing to read "Mahesh Agrawal", written over a circular stamp.

MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Torrent to Acquire Branded Business of India and Nepal from Unichem

Mumbai, 3rd November, 2017: Torrent Pharmaceuticals Limited ("Torrent") and Unichem Laboratories Limited ("Unichem") today announced that Torrent has entered into a definitive binding agreement with Unichem to acquire its branded business of India and Nepal ("India business") for a consideration of Rs.3600 Crores (Three Thousand Six Hundred Crores only), pursuant to the approval from the Board of Directors of the company earlier today.

Unichem's India business comprises of a portfolio of more than 120 brands in India and Nepal, manufacturing plant at Sikkim catering to these markets and all the employees engaged in the said business.

The transaction is ongoing concern basis by way of Slump sale.

Torrent will fund the acquisition through a mix of internal accruals and bank borrowings.

Unichem will continue to have greater focus on international business comprising of manufacturing, selling and marketing of fixed dosage formulation and API. It will also continue to build a sustainable revenue stream by investing in R&D to develop its future product pipeline.

This will be Torrent's fifth acquisition in India after acquiring the selected brands of Elder and Novartis, as well as Manufacturing Plants from ZygPharma and Glochem Industries Ltd. in the last four years.

In 2014 Torrent acquired a set of Elder brands. This was an important step in Torrent's growth journey. These brands have been successfully integrated. Over a period of three years, the acquired Elder brands has clocked a CAGR of 23% against the representative market growth of 11%. Shelcal and Chymoral the flagship brands acquired, have reached newer heights by crossing the 300cr and 100cr mark respectively and have been increasing their market shares consistently.

With this deal, Torrent will enter the list of top pharma firms in the Indian Pharma market (IPM) and will be ranked No 5 in the IMS. The acquisition helps Torrent to consolidate its market share in terms of sales which will increase from current 2.4% to 3.4% in the IPM.

As per the SMSRC prescription audit database, Torrent rank in terms of overall prescription in the Indian Pharma market will move from 14 to 7. Torrent will now be amongst the top 10 players in 15 out of the 20 specialties and amongst the top 5 in 7 key specialties respectively, further consolidating and improving its specialist focus.

The acquisition will add a brand of Rs. 200 Crores and three brands of more than Rs. 50 Crores, to its existing portfolio. The top brands include Losar, Unienzyme, Ampoxin, Telsar, Vizylac. In its existing key therapies, the market share in Cardiology, Central Nervous system, Gastro-Intestinal therapies will increase from 5.6% to 8.6%; 6.4% to 8.4% and 3.1% to 3.9% respectively. (AIOCD dataset)

Approximately- 3000 plus employees will get added to Torrent's existing employee pool. Also the distribution reach will enhance by the addition of 2000 stockists in the country.

This transaction will open doors for Torrent to enter into the OTC segment with the brand 'Unienzyme' and the Company will be a dominant player in the Digestive Enzyme market and will be amongst the top three players in the segments of Anti-Hypertensive, Anti-Depressants and Tranquilizers.

"The transaction is a strategic fit for Torrent and will strengthen its position in the key segments of Cardiology, Diabetology, Gastro-Intestinals and CNS therapies. It is also expected to realize cost and revenue synergies in Torrent's branded business in India" said Samir Mehta, Chairman Torrent Pharmaceuticals Limited.

